Disruption of Her2-Induced PD-L1 Inhibits Tumor Cell Immune Evasion in Patient-Derived Gastric Cancer Organoids
出版年份 2021 全文链接
标题
Disruption of Her2-Induced PD-L1 Inhibits Tumor Cell Immune Evasion in Patient-Derived Gastric Cancer Organoids
作者
关键词
-
出版物
Cancers
Volume 13, Issue 24, Pages 6158
出版商
MDPI AG
发表日期
2021-12-07
DOI
10.3390/cancers13246158
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Novel HER2-Directed Treatments in Advanced Gastric Carcinoma: AnotHER Paradigm Shift?
- (2021) Angela Dalia Ricci et al. Cancers
- Hedgehog transcriptional effector GLI mediates mTOR-Induced PD-L1 expression in gastric cancer organoids
- (2021) Vivien Koh et al. CANCER LETTERS
- MiR130b from Schlafen4+ MDSCs stimulates epithelial proliferation and correlates with preneoplastic changes prior to gastric cancer
- (2020) Lin Ding et al. GUT
- PD-L1 and HER2 Expression in Gastroesophageal Cancer: a Matched Case Control Study
- (2020) Andrea Beer et al. PATHOLOGY & ONCOLOGY RESEARCH
- Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trial
- (2020) Daniel V T Catenacci et al. LANCET ONCOLOGY
- Gastric cancer
- (2020) Elizabeth C Smyth et al. LANCET
- Significance of Detection of the HER2 Gene and PD-1/PD-L1 in Gastric Cancer
- (2020) Tian Yun et al. Journal of Oncology
- Formalin fixation on HER-2 and PD-L1 expression in gastric cancer: A pilot analysis using the same surgical specimens with different fixation times
- (2019) Keita Kai et al. World Journal of Clinical Cases
- A survival guide to HER 2 testing in gastric/gastroesophageal junction carcinoma
- (2019) Duminda Subasinghe et al. GASTROINTESTINAL ENDOSCOPY
- High-Plex Predictive Marker Discovery for Melanoma Immunotherapy–Treated Patients Using Digital Spatial Profiling
- (2019) Maria I. Toki et al. CLINICAL CANCER RESEARCH
- Expression Profile of Markers for Targeted Therapy in Gastric Cancer Patients: HER-2, Microsatellite Instability and PD-L1
- (2019) Marina Alessandra Pereira et al. Molecular Diagnosis & Therapy
- Methods and significance of the combined detection of HER2 gene amplification and chemosensitivity in gastric cancer
- (2018) Yang-Kun Wang et al. Cancer Biomarkers
- Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFNγ secretion
- (2018) Bharat K.R. Chaganty et al. CANCER LETTERS
- Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer
- (2018) Charles S. Fuchs et al. JAMA Oncology
- Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS
- (2018) K Muro et al. ANNALS OF ONCOLOGY
- Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604)
- (2018) Hiroshi Saeki et al. EUROPEAN JOURNAL OF CANCER
- Pembrolizumab for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction cancer: an evidence-based review of place in therapy
- (2018) Rutika Mehta et al. OncoTargets and Therapy
- PD-L1 and immune infiltrates are differentially expressed in distinct subgroups of gastric cancer
- (2018) H. K. Angell et al. OncoImmunology
- Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Yoon-Koo Kang et al. LANCET
- Protein Expression of Programmed Death 1 Ligand 1 and HER2 in Gastric Carcinoma
- (2017) Eiji Oki et al. ONCOLOGY
- EGFR or HER2 inhibition modulates the tumor microenvironment by suppression of PD-L1 and cytokines release
- (2017) Koung Jin Suh et al. Oncotarget
- Genomic alterations of ERBB receptors in cancer: clinical implications
- (2017) Rosalin Mishra et al. Oncotarget
- Hedgehog signaling regulates PDL-1 expression in cancer cells to induce anti-tumor activity by activated lymphocytes
- (2016) Hideya Onishi et al. CELLULAR IMMUNOLOGY
- An update on gastric cancer
- (2016) Syed A. Ahmad et al. CURRENT PROBLEMS IN SURGERY
- Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer
- (2016) Yaqing Zhang et al. GUT
- Schlafen 4–expressing myeloid-derived suppressor cells are induced during murine gastric metaplasia
- (2016) Lin Ding et al. JOURNAL OF CLINICAL INVESTIGATION
- Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
- (2016) Kei Muro et al. LANCET ONCOLOGY
- PD-L1 is an independent prognostic predictor in gastric cancer of Western patients
- (2016) Christine Böger et al. Oncotarget
- Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging
- (2016) Linda S. Steelman et al. Aging-US
- Poxvirus-Based Active Immunotherapy with PD-1 and LAG-3 Dual Immune Checkpoint Inhibition Overcomes Compensatory Immune Regulation, Yielding Complete Tumor Regression in Mice
- (2016) Susan P. Foy et al. PLoS One
- CD44 Plays a Functional Role in Helicobacter pylori-induced Epithelial Cell Proliferation
- (2015) Nina Bertaux-Skeirik et al. PLoS Pathogens
- Strategies and Advancements in Harnessing the Immune System for Gastric Cancer Immunotherapy
- (2015) Vinod Vijay Subhash et al. Journal of Immunology Research
- A Novel Multiple Tyrosine-kinase Targeted Agent to Explore the Future Perspectives of Anti-Angiogenic Therapy for the Treatment of Multiple Solid Tumors: Cabozantinib
- (2014) Subhajit Roy et al. Anti-Cancer Agents in Medicinal Chemistry
- PD-1 regulates extrathymic regulatory T-cell differentiation
- (2014) Xiufen Chen et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- (2014) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Tumor-specific cytotoxic T lymphocyte activity determines colorectal cancer patient prognosis
- (2014) Christoph Reissfelder et al. JOURNAL OF CLINICAL INVESTIGATION
- Cancer statistics, 2013
- (2013) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy
- (2013) Omid Hamid et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Modulation of CD8+ T-cell activation events by monocytic and granulocytic myeloid-derived suppressor cells
- (2013) Elio Schouppe et al. IMMUNOBIOLOGY
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- HER2 in gastric cancer: Comparative analysis of three different antibodies using whole-tissue sections and tissue microarrays
- (2013) Lucas Faria Abrahão-Machado WORLD JOURNAL OF GASTROENTEROLOGY
- Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
- (2012) Suzanne L Topalian et al. CURRENT OPINION IN IMMUNOLOGY
- Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes-A systematic review
- (2011) Terence C. Chua et al. INTERNATIONAL JOURNAL OF CANCER
- Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy
- (2011) J. Stagg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Gastric Cancer: An Infectious Disease
- (2010) M. Blanca Piazuelo et al. INFECTIOUS DISEASE CLINICS OF NORTH AMERICA
- Characterization of Cytokine-Induced Myeloid-Derived Suppressor Cells from Normal Human Peripheral Blood Mononuclear Cells
- (2010) M. G. Lechner et al. JOURNAL OF IMMUNOLOGY
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
- (2009) M. Ahmadzadeh et al. BLOOD
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started